셀렉타 바이오사이언시스CLRB 주가

[S-1/A] S-1/A — FORM S-1/A

[DEFA14A] DEFA14A — DEFA14A

[DEF 14A] 주주총회 위임장 — DEF 14A

Cellectar Biosciences Files Prospectus For Offering Of Up To 51.2M Shares Of Common Stock By Selling Stockholders

https://www.sec.gov/Archives/edgar/data/1279704/000110465926063918/tm2614975d1_s1.htm

[S-1] 증자/IPO 등록 — FORM S-1

♻️ 재탕[8-K] 중대 사건 — FORM 8-K

[PRE 14A] PRE 14A — PRE 14A

Ladenburg Thalmann Assumes Cellectar Biosciences at Buy, Announces Price Target of $10

Ladenburg Thalmann analyst Kevin DeGeeter assumes Cellectar Biosciences (NASDAQ:CLRB) with a Buy rating and announces Price Target of $10.

Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...

Cellectar Biosciences Inc (CLRB) showcases promising clinical progress and strategic financing, despite ongoing financial hurdles.

♻️ 재탕Cellectar Biosciences, Inc. Q1 2026 Earnings Call Summary

Moby summary of Cellectar Biosciences, Inc.'s Q1 2026 earnings call